NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Mission Bio

Mission Bio

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.missionbio.com/

Last Round

Early Funding

Aug 5, 2025

Total Funding Raised

$112M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Mission Bio is a life sciences company that develops and commercializes the Tapestri Platform, a precision genomics tool for high-throughput single-cell multi-omics analysis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

single-cell multi-omicssingle-cell sequencingTapestri platformgenomicsoncology researchgene therapyCRISPR analysisbioinformaticsmicrofluidicsbiomarker analysisclonal architecturesingle-cell DNAsingle-cell proteomicsprecision medicinelab automationrazor and blades

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mission Bio Comparables

Compare Mission Bio with similar companies based on industry and business-model similarity.

Mission Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Singleron Biotechnologies
90%
BioSkryb Genomics
86%
Atrandi Biosciences
80%

Mission Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingAug 5, 2025
Series CAug 13, 2020
GrantOct 10, 2019
Series BDec 13, 2018
Series AOct 17, 2017
Seed
Feb 6, 2017

Key People

Founding team and executive leadership

Adam Sciambi

Chief Technology Officer And Co-founder

Founding Team

Anjali pradhan

Chief Product Officer

Executive Team

Mission Bio Investors

Notable investors and investment history

Mission Bio investors
InvestorRounds
Soleus CapitalSeries C
Cota CapitalEarly Funding, Series B, Series C
National Cancer InstituteGrant
StartXSeries A
Keiretsu ForumSeries A, Seed
Ally Bridge GroupEarly Funding
Agilent VenturesEarly Funding, Series B, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 20, 2025

    New product announced at the ASH 2025 conference.

  • Nov 20, 2025

    Launched Tapestri Single-Cell Targeted DNA + RNA Assay at ASH 2025.

Mission Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mission Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mission Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range89
Year Founded2014
Last FundingAug 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.